Plain-English translation of NCT07035158 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
The DELIVER study investigated whether a breath test could help doctors detect liver cirrhosis at an earlier, more treatable stage. Researchers studied a special oral probe called EVOC that the body processes differently depending on whether someone has cirrhosis—similar to how different bodies digest foods differently. By analyzing chemicals exhaled in breath after taking the probe, the trial aimed to develop a simple, non-invasive way to identify cirrhosis before serious complications occur.
Currently, most patients don't learn they have cirrhosis until their liver is severely damaged and they arrive at an emergency room with life-threatening complications. Existing tests for cirrhosis are either invasive, uncomfortable, or not very accurate, so doctors need an easy, reliable tool that can catch the disease earlier—when treatments are still effective at preserving liver function and improving survival.
After confirming you were eligible, you received the EVOC probe by mouth—a special compound designed to be processed differently by healthy versus diseased livers. You then provided breath samples that researchers analyzed to detect chemical signatures of cirrhosis. The trial compared breath samples from people with confirmed cirrhosis to those suspected of having the disease, helping researchers develop a simple breath test for early detection.
AI-generated summary from trial data · Jul 14, 2026 · Not medical advice
United States
Chile
United Kingdom